D

r. Deborah Dunsire is a biopharma lifer, rising to the upper ranks of Novartis before taking the helm of Millennium Pharmaceuticals right up until its $8.8 billion sale to Takeda. Now she’s back to lead a fledging upstart called XTuit Pharmaceuticals, a preclinical outfit crafting therapies for cancer and fibrotic disease.

Dunsire has also long been an advocate for gender diversity in biotech, and on this, International Women’s Day, we asked her how far the industry has come and how far it has to go.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.